CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 28 enrolled
Drug / intervention
Palivizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01466062
NCT01466062Phase 3Completed
CompareCT.gov

Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

AbbVie (prior sponsor, Abbott)·interventional·Posted Nov 7, 2011·Updated Jun 17, 2013

In Brief

A Phase 3 clinical trial evaluating Palivizumab for Respiratory Syncytial Virus Infection. Completed, enrolled 28 participants across 6 sites.

Detailed Summary

To evaluate safety, efficacy and pharmacokinetics of palivizumab in children at the age of 24 months or less with immunocompromised medical conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Syncytial Virus Infection
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 7, 2011
Enrollment StartAug 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.7 years ago

Interventions

Palivizumabdrug